UG

UNITED GUARDIAN INC - 10-Q Summary (Period Ended June 30, 2010)

Business Context and Reporting Period

This is a Quarterly Report (Form 10-Q) for United-Guardian, Inc., a Delaware corporation engaged in the research, development, manufacturing, and marketing of cosmetic ingredients, personal care products, pharmaceuticals, and specialty industrial products. The reporting period covers the three and six months ended June 30, 2010. The company is classified as a smaller reporting company.

Key Financial Metrics

Cost of Sales Margin: Decreased to 38.5% for the six months ended June 30, 2010, from 40.9% in the prior year period.

Debt: The company reported no long-term debt payments during the period and no defaults on senior securities.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 6.1% for the six-month period and 24.8% for the three-month period compared to 2009. This was driven by a 24.7% increase in personal care product sales (specifically to partners ISP and Sederma), offset by a 16.4% decline in pharmaceutical sales due to timing of price increases.
• Pension Plan Termination: A significant one-time charge of $847,744 (before tax) was recorded for the termination of the company's Defined Benefit (DB) Pension Plan. This included a non-cash expense of $518,296 and a cash contribution of $337,378.
• Share Repurchase: The company spent $3,762,500 to acquire and retire 350,000 shares of stock from its President and largest shareholder, Kenneth H. Globus, at $10.75 per share. Additionally, 62,200 shares of treasury stock were retired.
• Liquidity: Cash and cash equivalents decreased by approximately $3.65 million, primarily due to the share repurchase and dividend payments totaling $3.07 million.
• Investment Income: Increased 21.6% for the six-month period, largely due to realized capital gains on the sale of marketable securities.

Guidance, Outlook, and Risks

Management Commentary: Management expects pharmaceutical sales volume to remain stable but anticipates an increase in the dollar value of sales for the remainder of 2010 due to a price increase implemented in April. Medical product sales are expected to be more evenly distributed throughout the year in 2010 compared to the front-loaded sales in 2009.

Outlook: The company believes its working capital is sufficient to support operations for at least the next twelve months. No significant capital expenditures are expected for the remainder of 2010. The company plans to continue using cash for dividends and marketable securities.

Risks and Contingencies:

• Concentration Risk: Approximately half of personal care products are sold outside the U.S., and sales are concentrated among a few marketing partners (ISP and Sederma).
• Product Competition: Risks include the development of superior products by competitors and lack of market acceptance for new products.
• Regulatory: The company is subject to examination by the IRS and New York State for tax years 2006 through 2009.

Investor Verification Checklist

• Pension Termination Impact: Verify the final settlement of the DB Plan termination and confirm no further liabilities remain beyond the $847,744 charge recorded.
• Pharmaceutical Sales Trend: Monitor Q3 and Q4 results to confirm the anticipated increase in pharmaceutical sales revenue following the April 2010 price hike.
• Shareholder Concentration: Note the reduction in shares outstanding following the repurchase from the largest shareholder and monitor for future capital allocation decisions (dividends vs. buybacks).
• Customer Concentration: Assess the stability of relationships with key partners ISP and Sederma, which drove the majority of personal care sales growth.
• Cash Position: Review the significant drawdown in cash reserves ($5.0M to $1.4M) to ensure liquidity remains adequate for ongoing operations and dividend commitments.